Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ1,24
KB-0,22
PKN97,6497,90,66
Msft0,61
Nokia4,724,7491,00
IBM0,13
Daimler AG57,7257,760,70
PFE0,71
22.9.2018 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 21.9.2018 22:00:00
Dicerna Pharm (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
15,99 -4,82 -0,81 1 259 642
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.9.2018
Popis společnosti
Obecné informace
Název společnostiDicerna Pharmaceuticals Inc
TickerDRNA
Kmenové akcie:Ordinary Shares
RICDRNA.O
ISINUS2530311081
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky30.6.2018
Počet zaměstnanců k 31.12.2017 44
Akcie v oběhu k 6.8.2018 52 949 660
Počet akcionářů k 31.3.2018 27
MěnaUSD
Kontaktní informace
Ulice87 Cambridgepark Dr
MěstoCAMBRIDGE
PSČ02140-2311
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon16 176 218 097
Fax13026365454

Business Summary: Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers, including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET).
Financial Summary: BRIEF: For the six months ended 30 June 2018, Dicerna Pharmaceuticals Inc revenues increased from $0K to $3.1M. Net loss applicable to common stockholders increased 34% to $51.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Litigation expense increase from $2.2M to $22.2M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 22.9.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardDavid Madden53
President, Chief Executive Officer, DirectorDouglas Fambrough46
Chief Financial Officer, Principal Financial OfficerJohn Green6218.4.20161.1.2016
Senior Vice President, Chief Scientific OfficerBob Brown501.1.2012
Senior Vice President - Product Strategy & OperationsTheodore Ashburn4717.12.201417.12.2014
Chief Medical OfficerPankaj Bhargava4631.3.201431.3.2014
Chief Medical OfficerRalf Rosskamp6315.6.201715.6.2017
Chief Business OfficerJames Weissman53